Novo Nordisk Receives EU Endorsement for Oral Wegovy Weight Loss Therapy
The European Medicines Agency's expert panel endorsed the oral version of Novo Nordisk’s (NVO) GLP-1 therapy, Wegovy, for weight loss. This regulatory approval could expand market access and increase demand for the drug in Europe.
Tickers: $NVO